1. Home
  2. INTA vs PHVS Comparison

INTA vs PHVS Comparison

Compare INTA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intapp Inc.

INTA

Intapp Inc.

HOLD

Current Price

$36.25

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.39

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTA
PHVS
Founded
2000
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
INTA
PHVS
Price
$36.25
$34.39
Analyst Decision
Buy
Buy
Analyst Count
7
11
Target Price
$41.43
$41.82
AVG Volume (30 Days)
800.4K
393.4K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
48.89
N/A
EPS
N/A
N/A
Revenue
$504,120,000.00
N/A
Revenue This Year
$15.91
N/A
Revenue Next Year
$13.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.09
N/A
52 Week Low
$19.01
$19.56
52 Week High
$47.93
$36.60

Technical Indicators

Market Signals
Indicator
INTA
PHVS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
INTA
PHVS

About INTA Intapp Inc.

Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: